Vanguard Portfolio Management’s Corcept Therapeutics CORT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$550M Sell
4,777,065
-267,573
-5% -$28.8M 0.02% 634
2026
Q2
$439M Buy
5,044,638
+224,070
+5% +$13.5M 0.02% 778
2026
Q1
$194M Buy
+4,820,568
New +$180M 0.01% 1157

Other funds holding CORT

Vanguard Portfolio Management's CORT Position: Q3 2026 in Review

Vanguard Portfolio Management reduced its Corcept Therapeutics (CORT) stake by 5.3% in Q3 2026, selling an estimated $28.8M and leaving 4,777,065 shares worth $550M. The position accounts for 0.02% of the portfolio, ranked #634.

Vanguard Portfolio Management first reported a position in CORT in Q1 2026 and has held it in 3 quarters since. 419 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

  • Vanguard Portfolio Management held 4,777,065 shares of Corcept Therapeutics worth $550M as of Q3 2026.
  • Vanguard Portfolio Management sold 267,573 Corcept Therapeutics shares in Q3 2026, an estimated $28.8M.
  • Corcept Therapeutics made up 0.02% of Vanguard Portfolio Management's portfolio in Q3 2026, its #634 holding.
  • Vanguard Portfolio Management first reported a position in Corcept Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 419 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on Vanguard Portfolio Management's 13F filing for Q3 2026, filed 13 Nov 2026.